Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SHBG | P04278 | 2/20 | 0.38 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11513027 | 0.80 | MAPK1 (0.67) | HSD17B3MAPK1ALDH1A1TP53MAPT | |
| SCHEMBL11513031 | 0.80 | MAPK1 (0.67) | HSD17B3MAPK1ALDH1A1TP53MAPT | |
| SCHEMBL18213715 | 0.80 | HSD17B3 (0.35) | HSD17B3MAPK1ALDH1A1TP53MAPT | |
| SCHEMBL16009870 | 0.80 | HSD17B3 (0.35) | HSD17B3MAPK1ALDH1A1TP53MAPT | |
| SCHEMBL16010046 | 0.80 | HSD17B3 (0.35) | HSD17B3MAPK1ALDH1A1TP53MAPT | |
| SCHEMBL16020098 | 0.79 | GPBAR1 (0.44) | HSD17B3MAPK1GPBAR1MEN1KMT2A | |
| SCHEMBL16010607 | 0.78 | GPBAR1 (0.62) | HSD17B3MAPK1GPBAR1MEN1KMT2A | |
| SCHEMBL16021332 | 0.76 | HSD17B3 (0.33) | HSD17B3MAPK1 | |
| SCHEMBL16010586 | 0.76 | HSD17B3 (0.33) | HSD17B3MAPK1 | |
| SCHEMBL18213705 | 0.75 | CYP19A1 (0.58) | HSD17B3MAPK1GPBAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326127-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | WASHINGTON UNIVERSITY | 2016-11-10 | — | — | US | disclosed |
| US-20160326127-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | WASHINGTON UNIVERSITY | 2016-11-10 | — | — | US | disclosed |
| US-9365502-B2 | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365502-B2 | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | disclosed |
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRB1, GABRB2 | HSD17B3 533/4885MAPK1 3917/4885ALDH1A1 563/4885 |
| US-20160326127-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRB1, GABRB2 | HSD17B3 533/4885MAPK1 3917/4885ALDH1A1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.